# DefEYE Secures Multi-Million Dollar Investment and Exclusive Sublicense from Celularity for BIOVANCE Ocular Allografts

> partnership · REPORTED · 2025-11-01

DefEYE Inc. secured a multi-million dollar investment and an exclusive sublicense of Celularity's BIOVANCE amnion-derived ocular allografts, strengthening the company's decellularized biologic portfolio for ocular surface disease and ophthalmic surgical applications. The collaboration is intended to accelerate commercialization of DefEYE's placental tissue solutions for eye care.

About Celularity / DefEYE Inc.: DefEYE Inc. is a privately held ophthalmic biologics company that commercializes decellularized biologic solutions including BIOVANCE and BIOVANCE 3L Ocular for the treatment of ocular surface diseases and surgical recovery, serving ophthalmologists and optometrists nationwide.

- Company: Celularity / DefEYE Inc.
- Sector: medical devices
- Primary source: https://glance.eyesoneyecare.com/stories/?organizations=DefEYE,+Inc

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.